MarketWatch (press release) The study, called MILO (MEK Inhibitor in Low Grade Serous Ovarian Cancer), will evaluate the efficacy and safety of MEK162 compared to standard chemotherapy treatments and is designed for worldwide regulatory submissions, including with the U.S. Food ... and more »
MarketWatch (press release) About Novartis Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological , central nervous system, bone ... and more »
CIT Magazine Dermatology 2013 (8-11 May 2013) for 2,100 delegates; the European Society for Dermatological Research (ESDR); the Japanese Society for Investigative Dermatology (JSID) and the Society for Investigative Dermatology (SID) of the United States. Other ...
HealthNewsDigest.com Applying the combined knowledge and industry expertise of our people in Shawnee, KS and new employees in St. Joseph, MO allows us to offer a more integrated approach to providing high quality dermatological and nutritional supplement products to pet ... and more »
PR Newswire (press release) The study, called MILO (MEK Inhibitor in Low Grade Serous Ovarian Cancer), will evaluate the efficacy and safety of MEK162 compared to standard chemotherapy treatments and is designed for worldwide regulatory submissions, including with the U.S. Food ...
ITCM The quinquennial event has brought 2,100 delegates to Scotland from the European Society for Dermatological Research (ESDR), the Japanese Society for Investigative Dermatology (JSID) and the Society for Investigative Dermatology (SID) of the United ... and more »
Private Equity Hub (press release) Letters of transmittal with respect to the Consolidation will be mailed out to all registered shareholders by the Company's transfer agent , Canadian Stock Transfer Company Inc. (“CST”). The letter of transmittal ... Synera is a topical patch that ...
PipelineReview.com (press release) The study, called MILO (MEK Inhibitor in Low Grade Serous Ovarian Cancer), will evaluate the efficacy and safety of MEK162 compared to standard chemotherapy treatments and is designed for worldwide regulatory submissions, including with the U.S. Food ... and more »
